Carna Biosciences Inc.

Kobe-shi, Japan

Carna Biosciences Inc.

Kobe-shi, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Carna Biosciences Inc. | Date: 2015-01-26

Provided is a pharmaceutical composition comprising a Cdc7 inhibitor and an M phase promoter. In particular, the Cdc7 inhibitor contained in the pharmaceutical composition is a furanone derivative represented by formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, A is COOR1 or a hydrogen atom; R1 is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic condensed ring, or an optionally substituted amino group. Alternatively, R2 and R3 may, together with the nitrogen atoms bonding the same, form an optionally substituted heterocycle or optionally substituted heterocyclic condensed ring. R4 is a hydrogen atom or halogen atom. However, if A is COOR1, R2 and R3 are not both simultaneously optionally substituted amino groups. When A is a hydrogen atom, R3 is a hydrogen atom.)


Patent
SBI Biotech Co. and Carna Biosciences Inc. | Date: 2014-02-05

To provide a novel furanone derivative, and a medicine including the same. The furanone derivative is represented by the formula (I):


Patent
Carna Biosciences Inc. | Date: 2016-06-01

The purpose of the present invention is to provide a novel triazine derivative of the formula (I):R^(1) represents a substituted or unsubstituted lower alkyl group,R^(2) represents a hydrogen atom or a substituted or unsubstituted lower alkyl group,A represents a nitrogen atom or C-R^(3),R^(3) represents a hydrogen atom, a cyano group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, or a substituted or unsubstituted carbamoyl group, andR^(4) represents a substituted or unsubstituted lower alkyl group,or a substituted or unsubstituted cycloalkyl group,or a pharmaceutically acceptable salt thereof.


Patent
Carna Biosciences Inc. | Date: 2015-01-14

To provide a novel triazine derivative represented by the following formula (I):A triazine derivative represented by the following formula (I) :R^(1) represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a substituted or unsubstituted heterocyclic fused ring, or a substituted or unsubstituted alkynyl group,R^(2) represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group,R^(3) represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heterocyclic fused ring,R^(4) represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, or a halogen atom, andR^(5) represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, or R^(1) and R^(5) may be combined to form a saturated or unsaturated 5- to 6-membered ring, thereby forming a multiply fused ring,or a pharmaceutically acceptable salt thereof.


Patent
Carna Biosciences Inc. | Date: 2016-12-07

Provided is a pharmaceutical composition comprising a Cdc7 inhibitor and an M phase promoter. In particular, the Cdc7 inhibitor contained in the pharmaceutical composition is a furanone derivative represented by formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, A is -COOR1 or a hydrogen atom; R1 is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic condensed ring, or an optionally substituted amino group. Alternatively, R2 and R3 may, together with the nitrogen atoms bonding the same, form an optionally substituted heterocycle or optionally substituted heterocyclic condensed ring. R4 is a hydrogen atom or halogen atom. However, if A is -COOR1, R2 and R3 are not both simultaneously optionally substituted amino groups. When A is a hydrogen atom, R3 is a hydrogen atom.)


Patent
Carna Biosciences Inc. | Date: 2016-07-27

To provide a novel triazine derivative represented by the following formula (I):A triazine derivative represented by the following formula (I) :R^(1) represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group,Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group,either of Z^(1) and Z^(2) represents carbon atom and the other is nitrogen atom, or both of the Z^(1) and Z^(2) represent nitrogen atoms,Q is selected from a structure (a) and (b) described below:^(2) represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group,R^(3) represents a hydrogen atom or a halogen atom,Y represents a nitrogen atom or a carbon atom, andthe bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond,or a pharmaceutically acceptable salt thereof.


Patent
Carna Biosciences Inc. | Date: 2014-09-01

To provide a novel 2,6-diaminopyrimidine derivative by the following formula (I): A 2,6-diaminopyrimidine derivative is represented by the formula (I): wherein R^(1 )represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group,Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group,Z^(1 )and Z^(2 )represent carbon atoms, or either 1 or 2 of the Z^(1 )and Z^(2 )represent nitrogen atoms,Q is selected from a structure (a) or (b) described below: R^(2 )represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group,R^(3 )represents a hydrogen atom or a halogen atom,Y represents a nitrogen atom or a carbon atom, and the bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond.


Patent
Carna Biosciences Inc. | Date: 2016-07-13

To provide a novel 2,6-diaminopyrimidine derivative by the following formula (I):A 2,6-diaminopyrimidine derivative is represented by the formula (I):R^(1) represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group,Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group,Z^(1) and Z^(2) represent carbon atoms, or either 1 or 2 of the Z^(1) and Z^(2) represent nitrogen atoms,Q is selected from a structure (a) or (b) described below:^(2) represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group,R^(3) represents a hydrogen atom or a halogen atom,Y represents a nitrogen atom or a carbon atom, andthe bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond.


Patent
Carna Biosciences Inc. | Date: 2014-09-12

To provide a novel triazine derivative represented by the following formula (I): wherein R^(1 )represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group,Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group,either of Z^(1 )and Z^(2 )represents carbon atom and the other is nitrogen atom, or both of the Z^(1 )and Z^(2 )represent nitrogen atoms,Q is selected from a structure (a) and (b) described below: wherein R^(2 )represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group,R^(3 )represents a hydrogen atom or a halogen atom,Y represents a nitrogen atom or a carbon atom, andthe bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond, or a pharmaceutically acceptable salt thereof.


Patent
Carna Biosciences Inc. and National Cancer Center | Date: 2016-10-12

The present invention provides a quinazoline derivative represented by the following formula (I):^(1) and R^(2) represent a hydrogen atom, a halogen atom, or a lower alkyl group optionally having a substituent; Z represents a cycloalkyl group having a substituent or a cycloalkenyl group having a substituent; and Q represents a bicyclic heteroaryl group optionally having a substituent, or a pharmaceutically acceptable salt thereof. Since the compound has an inhibitory effect on the Wnt/-catenin signaling pathway and exhibits an antitumor effect, it is useful as a medicine.

Loading Carna Biosciences Inc. collaborators
Loading Carna Biosciences Inc. collaborators